Journal
Nature Communications
Publication Date
7-2-2022
Volume
13
Issue
1
First Page
3824
Document Type
Open Access Publication
DOI
10.1038/s41467-022-31615-7
Rights and Permissions
Case, J.B., Mackin, S., Errico, J.M. et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun 13, 3824 (2022). https://doi.org/10.1038/s41467-022-31615-7 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Case, James Brett; Mackin, Samantha; Errico, John M; Chong, Zhenlu; Madden, Emily A; Whitener, Bradley; Jung, Ana; Droit, Lindsay; Handley, Scott A; Fremont, Daved H; Virgin, Herbert W; Diamond, Michael S; and et al, "Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains." Nature Communications. 13, 1. 3824 (2022).
https://digitalcommons.wustl.edu/oa_4/56
Supplementary information
41467_2022_31615_MOESM2_ESM.pdf (3310 kB)
Peer Review File
41467_2022_31615_MOESM3_ESM.pdf (1459 kB)
Reporting Summary
41467_2022_31615_MOESM4_ESM.zip (3860 kB)
Source Data
